Carpenter, D.E. (2020) 5-MeO-DMT: The 20-Minute Psychoactive Toad Experience That's Transforming Lives (Forbes Magazine). - This article summarizes various experiences of individuals who sustained enhancement of satisfaction with life, and easing of anxiety, depression and post-traumatic stress disorder (PTSD) after a 20-minute experience with Bufo 5-MeO-DMT. https://www.forbes.com/sites/davidcarpenter/2020/02/02/5-meo-dmt-the-20-minute-psychoactive-toad-experience-thats-transforming-lives/?sh=60c26ecb38a1

Reckweg, J.T. et al (2022) The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT). - The study established that improvements in mental health outcomes following a single exposure to Bufo 5‐MeO‐DMT can sustain for months. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314805/

Davis, AK. et al (2019) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. - This study found that 80% of study individuals diagnosed with depression and 79% of study individuals diagnosed with anxiety had a reduction after administration of Bufo 5-MeO-DMT in a group naturalistic setting with procedures similar to those conducted in a clinical trial with proper prepration and post integration of their experience. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430661/

Jefferson, S.J et al (2023). 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. - The article highlights the potential of Bufo 5-MeO-DMT to modulate innate behaviors and induce structural changes in the brain. These findings contribute to the understanding of the effects of 5-MeO-DMT on behavioral and neural plasticity levels. https://www.psypost.org/2023/05/psychedelic-substance-5-meo-dmt-induces-long-lasting-neural-plasticity-in-mice-163745

Reckweg, J. et al (2021) A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers. - The article highlights the preliminary safety and psychoactive effects of vaporized Bufo 5-MeO-DMT. The findings of the study suggest that Bufo 5-MeO-DMT was generally well-tolerated by the participants. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667866/

Carhart-Harris, R.L., et al. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. - This study explored the use of psilocybin for individuals with treatment-resistant depression. The findings indicated that psilocybin, when administered alongside psychological support, led to improvements in depressive symptoms and overall mood. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(16)30065-7/fulltext

Griffiths, R et. al (2020) Johns Hopkins Medicine researchers report that two doses of the psychedelic substance psilocybin, given with supportive psychotherapy, produced rapid and large reductions in depressive symptoms, with most participants showing improvement and half of study participants achieving remission through the four-week follow-up. https://www.hopkinsmedicine.org/news/newsroom/news-releases/psychedelic-treatment-with-psilocybin-relieves-major-depression-study-shows

Davis AK, et al. (2021) Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. - The findings of the study showed that compared to the placebo group, the psilocybin-assisted therapy group experienced greater reductions in depressive symptoms. At the end of the four-week follow-up period, 71% of the psilocybin group had a response to treatment, defined as a reduction of at least 50% in their depressive symptoms, compared to 0% in the placebo group. Moreover, 54% of the psilocybin group achieved remission, meaning they no longer met the diagnostic criteria for major depression disorder, compared to 0% in the placebo group. https://pubmed.ncbi.nlm.nih.gov/33146667/

McCartney, A. M., McGovern, H. T., & De Foe, A. (2022). Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions. - The study highlights the growing body of evidence supporting the potential of psychedelic-assisted therapy as a promising treatment approach for major depressive disorder. The study also addresses the potential mechanisms of action underlying the therapeutic effects of psychedelics, such as psilocybin, including neuroplasticity, increased emotional insight, and enhanced emotional processing. It emphasizes the importance of integrating these compounds within a therapeutic context, highlighting the role of psychotherapy in maximizing their benefits. https://akjournals.com/view/journals/2054/6/1/article-p10.xml

Gukasyan N, et al. (2022) Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. - The findings showed that psilocybin-assisted treatment resulted in significant reductions in depressive symptoms that persisted throughout the 12-month follow-up period. At the three-month follow-up, 70% of participants had achieved a response, defined as a reduction of at least 50% in depressive symptoms. Furthermore, at the 12-month follow-up, 57% of participants maintained a response. https://journals.sagepub.com/doi/10.1177/02698811211073759?icid=int.sj-abstract.similar-articles.1

Santos, R. G., et. al. (2007). Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness. - This study assessed the effects of Ayahuasca on anxiety, panic-like symptoms, and hopelessness. The results showed that Ayahuasca consumption led to a reduction in anxiety and hopelessness scores, suggesting its potential therapeutic value in addressing these symptoms. https://pubmed.ncbi.nlm.nih.gov/17532158/

Osorio, F., et al. (2015) - Antidepressant effects of a single dose of ayahuasca in treatment-resistant depression: a pilot study. In this pilot study, researchers explored the antidepressant effects of Ayahuasca in individuals with treatment-resistant depression. The findings indicated that Ayahuasca administration resulted in significant reductions in depressive symptoms, with some participants experiencing remission of depression. The study highlights the potential of Ayahuasca as an alternative treatment option for individuals who do not respond to conventional antidepressants. https://www.scielo.br/j/rbp/a/ghG6Q7cLTgSRF6JxJjj6LMS/?format=pdf

Sanches, R.F. et al. (2016) Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression - The researchers found that a single dose of Ayahuasca led to significant reductions in depressive symptoms that lasted up to three weeks following the session. https://journals.lww.com/psychopharmacology/Abstract/2016/02000/Antidepressant_Effects_of_a_Single_Dose_of.13.aspx

Palhano-Fontes, F., et. al. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. - This randomized placebo-controlled trial investigated the antidepressant effects of Ayahuasca in individuals with treatment-resistant depression. The study found that a single dose of Ayahuasca led to rapid and significant improvements in depressive symptoms compared to a placebo, supporting its potential as a therapeutic intervention for depression. https://pubmed.ncbi.nlm.nih.gov/29903051/

Uthaug, MV. et al. (2022) The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. - The results showed mescaline (San Pedro cactus) may induce profound and transformative experiences that could lead to increased self-awareness, emotional healing, and personal growth. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902264/

Agin-Liebes G, et. al. (2021) Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. - The study results showed mescaline may facilitate improvements in self-reported depression, anxiety, PTSD, and substance use disorders. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033766/